An ad hoc committee of 6-8 members will plan and conduct a public workshop to discuss the application of a Dietary Reference Intake (DRI)or DRI-like process to bioactive food substances (bioactives), also termed non-essential nutrients and phytochemicals. The workshop will focus on the DRI process and how that process could be applied to bioactives. The overall goal of the workshop is to identify the primary issues involved in a review process for bioactives and to examine each component of the DRI process and how bioactives may be considered compared to established nutrients. The workshop will make available to the key federal agencies critical information needed to decide whether or not such a process should be applied to bioactives. Questions relevant to workshop discussions are:
1. Why are bioactive substances important?
a. How are bioactives similar to and different from established nutrients?
b. What role might bioactives play in health promotion and disease prevention?
2. What is needed in order to consider a bioactive for a DRI-like process? This information would involve discussion of "entry into the system." Specific questions would include:
a. Is it necessary to have a common method for measuring bioactives in blood, etc.?
b. Is a database with bioactives in foods needed to consider a bioactive for a DRI value?
i. Is it essential to have food intake data?
ii. How would bioactives as components of a complex mixture be evaluated?
c. What types of studies will be needed for considering bioactives for DRI or DRI-like values?
i. Epidemiological evidence?
ii. Clinical trials?
3. What evaluation processes are available and how could they be applied to setting guidelines for bioactives?
a. What is the role of the DRI process in evaluating bioactives?
i. Do bioactives differ from established nutrients as candidates for an adequate intake (AI)?
b. How would an evidence-based review approach be used to evaluate bioactives for a DRI-like process? Examples to consider include:
i. FDA's reviews for health claims
ii. EFSA's reviews for health claims
iii. WHO's review for bioactives
iv. China's review for bioactives
c. Should a new paradigm be considered for evaluating bioactives?
A workshop summary will be prepared that summarizes the presentations and discussions at the event.